Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial by unknown
POSTER PRESENTATION Open Access
Comparative study of sequential intravesical
chemotherapy using gemcitabine and
mitomycin C with mitomycin C alone for
non-muscle invasive bladder carcinoma- a
randomized trial
Kumar Jayant*, Santosh Kumar, Shrawan kumar Singh, Swati Agrawal, Rajendra Agrawal
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Introduction
This study was conducted to investigate the ablative effi-
cacy and safety of sequential intravesical gemcitabine
and mitomycin C with mitomycin C alone in refractory
non-muscle invasive bladder cancer (NMIBC).
Methods
A total of 219 patients with refractory NMIBC were
prospectively enrolled at tertiary academic center over
period of Feb 2009-Jan 2012 & followed for next 3 yrs.
They were randomly assigned to either of treatment
arms: Gentamycin & mitomycin C (group A) or mito-
mycin C (group B). All patients underwent a 6-week
induction regimen followed by a monthly maintenance
regimen for one year if they responded to the induction
course.
Results
In Group A 98 of 102 & in group B 94 of 96 patients
completed the therapy and were evaluated for response
while 6 patient left the therapy in between. The therapy
was well tolerated in the rest of patients. In group‘A’ i.e
Gentamycin & mitomycin C a total, 82 patients
(83.67%) exhibited a complete response to intravesical
therapy. In 12.2% (12) patients had biopsy proven recur-
rence (22±6.16 months). In group ‘B’ (mitomycin C),
63 (65.60%) patients exhibited a complete response to
intravesical therapy, 22 patients (22.9%) showed a partial
response. During follow-up, 16 patients (25.3%)
developed recurrence within this period. (14.5 +/- 8.26
months).
Conclusions
Chemoresection with sequential intravesical gemcitabine
and mitomycin C administration may be a viable option
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Table 1 Detail parameters of both groups.





Total patients 102 96 NS+
Male 81 78 NS+
Female 21 19 NS+
Age 65.7±9.8 yrs 63.9±8.9 yrs NS+
Mean Duration of follow
up
36 months 36 months
Mean size of tumor <2cm 63 58 NS+
Mean sixe of tume >2 cm 39 38 NS+
Stage Ta 60 58 NS+
Stage T1 42 38 NS+
Grade 1 19 17 NS+
Grade 2 63 61 NS+







Actual complete response 83.67% (82) 65.6% (63) 0.001*
Recurrence % 12.2% (12) 25.3% (16) 0.001*





8-36 months 4-14 months
Values are presented as mean (+/- standard devitation)
Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)
Group B: Mitomycin C(MMS)
*Statistical significance was analyzed by student t-test
+Statistical significance was analyzed by the chi-square test.
Table 2 Details of adverse effects of therapy in both
groups.
Parameters Group A Group B P value
Gemcitabine + MMC Mitomycin C(MMC)
Dysuria 11.7% (12) 7.2% (7) NS+
Suprapubic pain 11.7% (12) 9.3% (9) NS+
Hematuria 3.9% (4) 3.1% (3) NS+
Chemical Cystitis 7.8% (8) 6.25% (6) NS+
Local reaction 6.8% (7) 4.16% (4) NS+
Skin reaction 5.8% (6) 4.16% (4) NS+
Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)
Group B: Mitomycin C(MMS)
*Statistical significance was analyzed by student t-test
+Statistical significance was analyzed by the chi-square test.
Figure 2 CONSORT diagram showing the participants through each
stage of a randomized trial.
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